Retatrutide, Amylin Analogs, and the Rise of Muscle-Preserving Research

Retatrutide continues to be one of the most closely watched molecules in cardiometabolic research because of its triple-action GLP-1, GIP, and glucagon receptor activity.

In March 2026, Eli Lilly announced Phase 3 topline success in TRANSCEND-T2D-1. In adults with Type 2 Diabetes, the 12 mg dose achieved 16.8% average weight loss and up to a 2.0% A1C reduction over 40 weeks.

The most interesting signal is the apparent lack of a clear weight-loss plateau by the 40-to-48-week mark, which suggests the long-term curve may still have room to develop.

While Retatrutide is receiving much of the attention, long-acting amylin analogs are becoming a major area of interest because they may offer a different tolerability profile than classic GLP-1 approaches.

Petrelintide, also referenced in some research commentary as Petrelinitide, is being studied as an option for those focused on GLP-1 gastrointestinal tolerability challenges. Phase 2 data reported approximately 10.7% weight loss with placebo-like tolerability.

Bimagrumab is a monoclonal antibody that binds Activin Type II receptors. By blocking those receptors, it reduces signaling from myostatin and activin pathways involved in muscle breakdown.

In Phase 2 BELIEVE data, researchers paired Bimagrumab with Semaglutide. The combination group reported that 92.2% of total weight loss came from fat mass, substantially protecting lean mass compared with what is often observed in weight-loss-only approaches.

Bimagrumab monotherapy also showed an increase in total body lean mass while participants were in a caloric deficit. Reported side effects were primarily muscle spasms, cramps, and mild acne.

Apitegromab takes a more selective approach by targeting pro-myostatin, the precursor form of myostatin, rather than broadly blocking the receptor itself.

This strategy is being watched because it may reduce off-target activity in tissues such as the heart or bones while still supporting lean-mass preservation. EMBRAZE trial data reported greater lean-mass preservation when Apitegromab was studied alongside Tirzepatide.

Regeneron is studying a cocktail-style approach that combines Semaglutide with Trevogrumab and Garetosmab to evaluate whether dual inhibition can support fat loss while reducing muscle-loss-associated metabolic slowdown.

Biohaven is developing Taldefgrobep Alfa, a fusion protein designed to act as a decoy by binding myostatin before it can reach muscle tissue. Phase 2 topline results are expected in the second half of 2026.

The next phase of metabolic peptide research is no longer focused only on total weight loss. The emerging goal is better body composition: more fat loss, less lean mass loss, improved tolerability, and stronger long-term metabolic outcomes.

Triple agonists, amylin analogs, and myostatin inhibitors may define the next chapter of cardiometabolic research.